Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)
To evaluate the efficacy and safety of TQ-B3139 versus crizotinib in subjects with ALK-positive NSCLC that have received one chemotherapy regimen and have not received ALK inhibitor.
ALK-positive NSCLC
DRUG: TQ-B3139|DRUG: Crizotinib
Progression-Free Survival (PFS), PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause., up to 36 months
Objective Response Rate (ORR), Percentage of subjects achieving complete response (CR) and partial response (PR)., up to 36 months|Disease Control rate (DCR), Percentage of subjects achieving CR, PR, stable disease (SD) and Non-CR/Non-progressive disease (PD), up to 36 months|Overall Survival (OS), OS defined as the time from randomization to death from any cause. Subjects who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive., up to 36 months
To evaluate the efficacy and safety of TQ-B3139 versus crizotinib in subjects with ALK-positive NSCLC that have received one chemotherapy regimen and have not received ALK inhibitor.